Medical big guns help Proteomics rev up Aussie cancer test rollout
The Board of Directors includes the main surgeon of the United Kingdom, Professor Hugh Barr, investigator of the Surveillance Study of the esophagus of Barrett, and his colleague of Barrett, professor Krish Ragunath, a specialist in Esophagea management.
The Group also includes the Dutch pioneer in the Esophageal Cancer Imaging and in the development of biomarkers, Professor Jacques Bergman and the thoracic surgeon based in the United States, Professor Andrew Chang, Mayo Clinic to the researcher and gastrointere Professor Prasad Iyer, surgery specialist of the hole of the hole hole of the Buco, Daniela Molen and Molena pathogeneous, Robert Odze.
The Director of the CEO of Proteomics International Richard Lipscombe said: “Their competence and their clinical intuitions will be precious as we introduce Promarkerse to the global markets and we commit ourselves to having a significant impact on the lives of people who live with chronic acid reflux.”
With the technology ready for the market, the regulation takes place on the Board of Directors and now a world-class consultancy team in its corner, the company has firmly planted its flag as non-non-non-pronouncer in the first detection of cancer and precision medicine-point by saving life in the process.
Is your company listed in Asx doing something interesting? Contact: matebirney@bullsnbears.com.au
